ERBB2 and non-small cell lung carcinoma: The standard of care of stage IV NSCLC involves platinum-based doublet chemotherapy and targeted therapies (some of which not yet available outside of clinical trials) in the presence of sensitizing alterations in EGFR, ALK, ROS-1, and BRAF5 or, more recently, NTRK gene fusions, RET rearrangements6, MET amplification or mutation, ERBB2 (HER2) mutation.